SMITH & NEPHEW ANNUAL REPORT 2015 www.
com 112 OVERVIEW OUR BUSINESS OUR PERFORMANCE GOVERNANCE OUR FINANCIALS GROUP FINANCIAL STATEMENTS Group income statement Year ended Year ended Year ended 31 December 31 December 31 December 2015 2014 2013 Notes $ million $ million $ million Revenue 2 4,634 4,617 4,351 Cost of goods sold 1,143 1,162 1,100 Gross profit 3,491 3,455 3,251 Selling, general and administrative expenses 3 2,641 2,471 2,210 Research and development expenses 3 222 235 231 Operating profit 2 & 3 628 749 810 Interest income 4 11 13 14 Interest expense 4 49 35 10 Other finance costs 4 15 11 11 Share of results of associates 11 16 2 1 Profit before taxation 559 714 802 Taxation 5 149 213 246 1 Attributable profit for the year 410 501 556 1 Earnings per ordinary share 6 Basic 45.9 56.1 61.7 Diluted 45.6 55.7 61.4 Group statement of comprehensive income Year ended Year ended Year ended 31 December 31 December 31 December 2015 2014 2013 Notes $ million $ million $ million 1 Attributable profit for the year 410 501 556 Other comprehensive income: Items that will not be reclassified to income statement Re-measurement of net retirement benefit obligations 18 8 94 12 Taxation on other comprehensive income 5 10 19 16 Total items that will not be reclassified to income statement 2 75 4 Items that may be reclassified subsequently to income statement Cash flow hedges interest rate derivatives losses arising in the year 5 Cash flow hedges forward foreign exchange contracts gains losses arising in the year 34 31 8 gains transferred to inventories for the year 50 14 3 Exchange differences on translation of foreign operations 176 196 6 Total items that may be reclassified subsequently to income statement 192 184 1 Other comprehensive expense income for the year, net of taxation 190 259 5 1 Total comprehensive income for the year 220 242 551 1 Attributable to equity holders of the Company and wholly derived from continuing operations.
THE NOTES ON PAGES 119 TO 166 ARE AN INTEGRAL PART OF THESE ACCOUNTS.
com 113 OVERVIEW OUR BUSINESS OUR PERFORMANCE GOVERNANCE OUR FINANCIALS GROUP FINANCIAL STATEMENTS Commentary on the Group income statement and Group statement of comprehensive income Revenue Operating profit Group revenue increased by $17m, 0% on a reported basis, from Operating profit decreased by $121m from $749m in 2014 to $628m $4,617m in 2014 to $4,634m in 2015. in2015.
The underlying increase is 4%, after adjusting for the 4% impact of This movement was primarily driven by the benefits of the Group acquisitions and the 8% attributable to the unfavourable impact of Optimisation programme and synergies from the ArthroCare acquisition currency movements.
in 2014, offset by the costs relating to anticipated and settled metal-onmetal hip claims.
Established Markets had an underlying growth of 3% and Emerging Markets had an underlying growth of 11%, both of which contributed to Interest income expense the Group increase of 4%.
Net interest expense increased by $16m from a net $22m expense in Cost of goods sold 2014 to a net $38m expense in 2015.
This movement is primarily due to an increase in interest expense due to the financing of the ArthroCare Cost of goods sold decreased by $19m, 2% on a reported basis, from acquisition in 2014.
The movement is primarily due to the strengthening of the US Dollar which more than offsets the increase Other finance costs in volume from acquisitions and underlying trading.
Other finance costs in 2015 increased by $4m and principally relates to During 2015, no restructuring and rationalisation expenses 2014 costs associated with the Groups retirement benefit schemes.
$12m and acquisition related costs 2014 $23m were charged to cost of goods sold.
Taxation Selling, general and administrative expenses The taxation charge decreased by $64m to $149m from $213m in 2014.
Selling, general and administrative expenses increased by $170m After adjusting for specific transactions that management considers 7% on a reported basis from $2,471m in 2014 to $2,641m in 2015. affect the Groups short-term profitability restructuring and The underlying movement is 7% after adjusting for net impact of 7% rationalisation expenses, amortisation of acquisition intangibles, from acquisitions and unfavourable currency movements of 7%.
acquisition related costs and legal and other items the tax rate on trading profit was 26.8% 2014 27.7%.
In 2015, administrative expenses included amortisation of software and other intangible assets of $66m 2014 $62m, $65m of restructuring and rationalisation expenses 2014 $49m, an amount of $204m relating to amortisation and impairment of acquired intangibles 2014 $129m, $12m of acquisition related costs 2014 $95m and $203m relating to anticipated and settled metal-on-metal hip claims and additional expenses primarily relating to the RENASYS distribution hold in the US.
These expenses were offset by a net gain of $33m relating to a patent litigation and past service and curtailment gains of $19m 2014 $46m arising on US and UK post-retirement benefits.
Research and development expenses Research and development expenditure as a percentage of revenue remained broadly consistent at 4.8% in 2015 2014 5.1%.
Actual expenditure was $222m in 2015 compared to $235m in 2014.
The Group continues to invest in innovative technologies and products to differentiate it from competitors.
THE FINANCIAL COMMENTARY ON THIS PAGE FORMS PART OF THE BUSINESS REVIEW AND IS UNAUDITED.
SEE PAGES 181 TO 182 FOR COMMENTARY ON THE 2014 FINANCIAL YEAR.
com 114 OVERVIEW OUR BUSINESS OUR PERFORMANCE GOVERNANCE OUR FINANCIALS GROUP FINANCIAL STATEMENTS Group balance sheet At At 31 December 31 December 2015 2014 Notes $ million $ million Assets Non-current assets Property, plant and equipment 7 932 891 Goodwill 8 2,012 2,027 Intangible assets 9 1,502 1,747 Investments 10 13 5 Investments in associates 11 115 112 Retirement benefit asset 18 13 7 Deferred tax assets 5 105 77 4,692 4,866 Current assets Inventories 12 1,217 1,181 Trade and other receivables 13 1,138 1,166 Cash at bank 15 120 93 2,475 2,440 Total assets 7,167 7,306 Equity and liabilities Equity attributable to owners of the Company Share capital 19 183 184 Share premium 590 574 Capital redemption reserve 12 11 Treasury shares 19 294 315 Other reserves 256 64 Retained earnings 3,731 3,650 Total equity 3,966 4,040 Non-current liabilities Long-term borrowings 15 1,434 1,666 Retirement benefit obligations 18 184 233 Other payables 14 29 44 Provisions 17 133 63 Deferred tax liabilities 5 77 98 1,857 2,104 Current liabilities Bank overdrafts and loans 15 46 39 Trade and other payables 14 842 838 Provisions 17 193 67 Current tax payable 263 218 1,344 1,162 Total liabilities 3,201 3,266 Total equity and liabilities 7,167 7,306 The accounts were approved by the Board and authorised for issue on 24 February 2016 and are signed on its behalf by: Roberto Quarta Olivier Bohuon Julie Brown Chairman Chief Executive Officer Chief Financial Officer THE NOTES ON PAGES 119 TO 166 ARE AN INTEGRAL PART OF THESE ACCOUNTS.
com 115 OVERVIEW OUR BUSINESS OUR PERFORMANCE GOVERNANCE OUR FINANCIALS GROUP FINANCIAL STATEMENTS Commentary on the Group balance sheet Non-current assets Non-current liabilities Non-current assets decreased by $174m to $4,692m in 2015 from Non-current liabilities decreased by $247m from $2,104m in 2014 to $4,866m in 2014.
This is principally attributable to the following: $1,857m in 2015.
This movement principally relates to: Property, plant and equipment increased by $41m from $891m in Long-term borrowing decreased from $1,666m in 2014 to $1,434m 2014 to $932m in 2015.
There were $303m of additions together with in2015 principally due to repayments of bank debt.
$6m acquired with the Colombia and Russia acquisitions which were The retirement benefit obligation decreased from $233m in 2014 to offset by $11m of assets disposed.
Depreciation of $226m was $184m in 2015 due to past cost adjustments arising from plan charged during 2015 and there were unfavourable currency amendments in the UK and US, increases in discount rates and movements of$31m.
Deferred tax liabilities decreased by $21m from $98m in 2014 to This movement relates to additions of $10m from the acquisition in $77m in 2015.
Refer to commentary within non-current assets for Colombia and $24m from the acquisition in Russia.
This was offset explanation of the net deferred tax position movement.
by unfavourable currency movements of $49m which decreased the overall goodwill balance.
The impact of the above was partly offset by an increase in Intangible assets decreased by $245m from $1,747m in 2014 to non-current provisions, primarily relating to the estimated costs to $1,502 in 2015.
There were additions of $55m in 2015 relating to resolve all future known and anticipated metal-on-metal hip claims.
intellectual property, distribution rights and software acquired together with $19m acquired with the Colombia and Russia Current liabilities acquisitions.
Amortisation and impairment during 2015 was $270m Current liabilities increased by $182m from $1,162m in 2014 and and there were unfavourable currency movements of $45m.
This movement is attributable to: Investments in associates increased to $115m from $112m in 2014.
Bank overdrafts and loans increased by $7m from $39m in 2014 to The increase was attributable to a capital contribution to Bioventus of $46m in 2015.
$25m and other investment gains of $2m, offset by an investment loss in Bioventus of $18m and a reclassification of an associate to Provisions increased by $126m from $67m in 2014 to $193m in 2015 investments of $6m due to a change in shareholding.
primarily due to an increase in legal provision for known and Deferred tax assets increased by $28m in the year from $77m in anticipated metal-on-metal hip claims.
The net deferred tax position has changed Current tax payables increased by $45m from $218m in 2014 to from a liability of $21m in 2014 to an asset of $28m in 2015.
The net $263m, mainly attributable to differences in the timing of cash tax movement of $49m is mainly due to the creation of the metal-onpayments year-on-year.
metal hip claim provision and amortisation of certain acquired intangibles, offset by a reduction in retirement benefit obligations.
Total equity Current assets Total equity decreased by $74m from $4,040m in 2014 to $3,966m in2015.
The principal movements were: Current assets increased by $35m to $2,475m from $2,440m in 2014.
The movement relates to the following: Total equity $ million Inventories rose by $36m to $1,217m in 2015 from $1,181 in 2014.
1 January 2015 4,040 This movement is driven by inventory acquired with the Colombia and Russia acquisitions and a general increase across the Emerging Attributable profit 410 Markets.
This was offset by unfavourable currency movements Currency translation losses 176 of$63m.
Hedging reserves 16 The level of trade and other receivables decreased by $28m to Actuarial losses on retirement benefit obligations 8 $1,138m in 2015 from $1,166m in 2014.
The movement primarily relates to the $17m increase in the bad debt provision as well as Dividends paid during the year 272 unfavourable currency movements.
Purchase of own shares 77 Cash at bank has increased by $27m from $93m in 2014 to $120m Taxation on other comprehensive income and in2015.
Refer to the Group cash flow statement and related equity items 15 commentary on pages 116 and 117 for further detail.
Net share-based transactions 50 31 December 2015 3,966 THE FINANCIAL COMMENTARY ON THIS PAGE FORMS PART OF THE BUSINESS REVIEW AND IS UNAUDITED.
com 116 OVERVIEW OUR BUSINESS OUR PERFORMANCE GOVERNANCE OUR FINANCIALS GROUP FINANCIAL STATEMENTS Group cash flow statement Year ended Year ended Year ended 31 December 31 December 31 December 2015 2014 2013 Notes $ million $ million $ million Cash flows from operating activities Profit before taxation 559 714 802 Net interest expense income 4 38 22 4 Depreciation, amortisation and impairment 493 427 361 Loss on disposal of property, plant and equipment and software 15 11 23 Distribution from trade investments 3 1 Share-based payments expense equity settled 23 29 32 28 Share of results of associates 11 16 2 1 Dividends received from associates 11 1 Profit on disposal of manufacturing facility 21 9 Net movement in post-retirement benefit obligations 57 81 27 Increase in inventories 83 168 99 Increase in trade and other receivables 26 76 70 Increase in trade and other payables and provisions 216 86 122 1 Cash generated from operations 1,203 961 1,138 Interest received 8 3 4 Interest paid 44 36 10 Income taxes paid 137 245 265 Net cash inflow from operating activities 1,030 683 867 Cash flows from investing activities Acquisitions, net of cash acquired 21 44 1,572 74 Capital expenditure 2 358 375 340 Investment in associate 11 25 2 Purchase of investments 10 2 4 Proceeds from associate loan redemption 188 Proceeds on disposal of manufacturing facility 21 20 Cash received on disposal of associate 7 Net cash used in investing activities 429 1,745 407 Cash flows from financing activities Proceeds from issue of ordinary share capital 16 40 48 Purchase of own shares 77 75 231 Proceeds from borrowings due within one year 20 42 30 12 Settlement of borrowings due within one year 20 26 52 6 Proceeds from borrowings due after one year 20 831 3,390 695 Settlement of borrowings due after one year 20 1,062 2,068 779 Proceeds from own shares 5 4 3 Settlement of currency swaps 20 15 11 1 Equity dividends paid 19 272 250 239 Net cash used in from financing activities 558 1,008 498 Net increase decrease in cash and cash equivalents 43 54 38 Cash and cash equivalents at beginning of year 20 65 126 167 Exchange adjustments 20 6 7 3 2 Cash and cash equivalents at end of year 102 65 126 1 Includes $52m 2014 $60m, 2013 $54m of outgoings on restructuring and rationalisation expenses, $36m 2014 $112m, 2013 $25m of acquisition-related costs and $3m 2014 $23m, 2013 $nil of legal and other costs.
2 Cash and cash equivalents is net of bank overdrafts of $18m 2014 $28m.
com 117 OVERVIEW OUR BUSINESS OUR PERFORMANCE GOVERNANCE OUR FINANCIALS GROUP FINANCIAL STATEMENTS Commentary on the Group cash flow statement The main elements of the Groups cash flow and movements in net Share buy-backs debt can be summarised as follows: During the year ended 31 December 2015, the Group purchased a total of 4.4m 2014 4.6m ordinary shares at a cost of $77m 2014 $75m.
Net cash inflow from operating activities Cash generated from operations in 2015 of $1,203m 2014 $961m, Liquidity and capital resources 2013 $1,138m is after paying out $36m 2014 $112m, 2013 $25m The Groups policy is to ensure that it has sufficient funding and of acquisition-related costs, $52m 2014 $60m, 2013 $54m of facilities in place to meet foreseeable borrowing requirements.
restructuring and rationalisation expenses and $3m 2014 $23m, 2013 $nil relating to legal and other costs.
At 31 December 2015, the Group held $102m 2014 $65m, 2013 $126m in cash net of bank overdrafts.
The Group had committed Capital expenditure facilities available of $2,425m at 31 December 2015 of which $1,425m was drawn.
Smith & Nephew intends to repay the amounts due within The Groups ongoing capital expenditure and working capital one year by using available cash and drawing down on the longer-term requirements were financed through cash flow generated by business facilities.
In addition, Smith & Nephew has finance lease commitments operations and, where necessary, through short-term committed and of $10m.
In 2015, capital expenditure on tangible and intangible fixed assets represented approximately 8% of continuing During the year ended 31 December 2014, the Group refinanced its Group revenue 2014 8%, 2013 8%.
The Group signed a new five-year committed $1bn multi-currency revolving credit facility with a maturity In 2015, capital expenditure amounted to $358m 2014 $375m, date of March 2019.
This maturity date has since been extended to 2013 $340m.
The principal areas of investment were the placement March 2020.
In April 2015, the Group signed a new three-year, $300m of orthopaedic instruments with customers, patents and licences, plant bilateral term loan with one of its relationship banks.
The new term loan and equipment and information technology.
has a maturity date of April 2018.
The proceeds of this new loan were At 31 December 2015, $24m 2014 $34m, 2013 $41m of capital used to repay the remaining outstanding amount on the committed expenditure had been contracted but not provided for which will be term loan used to fund the acquisition of ArthroCare.
The principal variations in the Groups borrowing requirements result from the timing of dividend payments, acquisitions and disposals of Acquisitions and disposals businesses, timing of capital expenditure and working capital fluctuations.
Smith & Nephew believes that its capital expenditure During the year ended 31 December 2015, the Group acquired needs and its working capital funding for 2016, as well as its other businesses in Colombia and Russia for consideration, net of cash known or expected commitments or liabilities, can be met from its acquired, of $44m.
In November 2015, the Group invested $25m existing resources and facilities.
The Groups net debt decreased from initsassociate, Bioventus.
$1,613m at the beginning of 2015 to $1,361m at the end of 2015, During 2014, the Group received repayment of the $160m loan note representing an overall decrease of $252m.
toBioventus and $28m of accrued interest.
Proceeds of $20m were The Groups planned future contributions are considered adequate received on the disposal of the Groups manufacturing plant in tocover the current underfunded position in the Groups defined Gilberdyke, UK.
Dividends The 2014 final dividend of 18.6 US cents per ordinary share totalling $166m was paid on 6 May 2015.
The 2015 interim dividend of 11.8 US cents per ordinary share totalling $106m was paid on 27 October 2015.
com 118 OVERVIEW OUR BUSINESS OUR PERFORMANCE GOVERNANCE OUR FINANCIALS GROUP FINANCIAL STATEMENTS Group statement of changes in equity Capital Share Share redemption Treasury Other Retained Total 2 3 capital premium reserve shares reserves earnings equity $ million $ million $ million $ million $ million $ million $ million At 31 December 2012 193 488 735 121 3,817 3,884 1 Attributable profit for the year 556 556 Other comprehensive income 1 4 5 Equity dividends declared and paid 239 239 Share-based payments recognised 28 28 Taxation on share-based payments 3 3 Purchase of own shares 231 231 Cost of shares transferred to beneficiaries 21 18 3 Cancellation of treasury shares 10 10 623 623 4 Issue of ordinary share capital 1 47 48 At 31 December 2013 184 535 10 322 120 3,520 4,047 1 Attributable profit for the year 501 501 Other comprehensive expense 184 75 259 Equity dividends declared and paid 250 250 Share-based payments recognised 32 32 Purchase of own shares 75 75 Cost of shares transferred to beneficiaries 25 21 4 Cancellation of treasury shares 1 1 57 57 4 Issue of ordinary share capital 1 39 40 At 31 December 2014 184 574 11 315 64 3,650 4,040 1 Attributable profit for the year 410 410 Other comprehensive income expense 192 2 190 Equity dividends declared and paid 272 272 Share-based payments recognised 29 29 Taxation on share-based payments 5 5 Purchase of own shares 77 77 Cost of shares transferred to beneficiaries 38 33 5 Cancellation of treasury shares 1 1 60 60 4 Issue of ordinary share capital 16 16 At 31 December 2015 183 590 12 294 256 3,731 3,966 1 Attributable to equity holders of the Company and wholly derived from continuing operations.
2 Refer to Note 19.2 for further information.
3 Other reserves comprises gains and losses on cash flow hedges, foreign exchange differences on translation of foreign operations and the difference arising as a result of translating share capital and share premium at the rate ruling on the date of redenomination instead of the rate at the balance sheet date.
The cumulative translation loss within other reserves at 31 December 2015 of $254m 2014 $78m loss, 2013 $118m gain.
4 Issue of ordinary share capital as a result of options being exercised.
